<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617213</url>
  </required_header>
  <id_info>
    <org_study_id>16043</org_study_id>
    <nct_id>NCT01617213</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma</brief_title>
  <acronym>AMM-2011</acronym>
  <official_title>Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy
      in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2)
      with autologous PBSC transplant.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study is no longer needed as recent data have answered the primary hypotheses for this study.
  </why_stopped>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Duration of time until patient experiences an event (recurrence, relapse or death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients that have complete and very good partial responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Duration of time from Day 0 until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade &gt; 2 toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Percent of patients experiencing one or more toxicity greater than 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>4 years</time_frame>
    <description>Percent of patients experiencing a definite or probable viral, fungal or bacterial infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related Mortality</measure>
    <time_frame>4 years</time_frame>
    <description>Number of patients that experience a death from causes other relapse or progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Maintenance Lenalidomide After Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>200 mg/m2/IV</description>
    <arm_group_label>Maintenance Lenalidomide After Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.</description>
    <arm_group_label>Maintenance Lenalidomide After Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 to 75 years of age.

          -  ECOG performance status of 0, 1 or 2.

          -  Patients who have a history of another malignant disorder are eligible, provided that
             they have not received active therapy for 5 years. Patients with basal cell and
             squamous cell skin cancers are eligible.

          -  Patients who are pregnant are ineligible.

          -  Patients must furnish written informed consent and HIPAA authorization for release of
             personal health information.

          -  Patients must be able to understand the requirements of the study, abide by the study
             restrictions, and agree to return for the required assessments.

          -  Patients must be HIV and HTLV-I,-II antibody sero-negative.

          -  Patients must have adequate visceral organ function

        Exclusion Criteria:

          -  Patients are ineligible if they have received cumulative chemotherapy doses in excess
             of: carmustine (BCNU) 400 mg/m2, or a cumulative anthracycline exposure in excess of
             550 mg/m2 Adriamycin (doxorubicin) unless the gated-pool radionuclide cardiac scan
             shows greater than/equal to 45% ejection fraction.

          -  Patients are ineligible if they are receiving any other investigational agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary J. Laughlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Mary Laughlin, MD</investigator_full_name>
    <investigator_title>Professor, Director of Stem Cell Transplant Program</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 11, 2016</submitted>
    <returned>March 10, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

